SCHEMBL31358744

SCHEMBL31358744

O=C1C(=Cc2ccc(-c3ccc(F)cc3[N+](=O)[O-])o2)C(=O)c2ccccc21

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 10/20 0.57
NPSR1 Q6W5P4 6/20 0.57
PKM P14618 4/20 0.57
KDM4E B2RXH2 4/20 0.57
BRAF P15056 1/20 0.55
MAPT P10636 11/20 0.52
MEN1 O00255 9/20 0.52
ALDH1A1 P00352 7/20 0.52
LMNA P02545 6/20 0.52
L3MBTL1 Q9Y468 6/20 0.52
HPGD P15428 5/20 0.52
MAPK1 P28482 3/20 0.52
RECQL P46063 1/20 0.52
HTRA2 O43464 1/20 0.52
CACNA1B Q00975 2/20 0.52
APBA1 Q02410 2/20 0.52
ALOX15 P16050 1/20 0.52
ALOX12 P18054 1/20 0.52
NTSR1 P30989 1/20 0.52
TDP1 Q9NUW8 3/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31358665 0.86 KMT2A (0.73) KMT2ANPSR1PKMKDM4EBRAF
SCHEMBL31358680 0.86 KMT2A (0.58) KMT2ANPSR1PKMKDM4EBRAF
SCHEMBL31358780 0.86 KMT2A (0.57) KMT2ANPSR1PKMKDM4EBRAF
SCHEMBL31358739 0.83 MAPT (0.64) KMT2ANPSR1PKMKDM4EBRAF
SCHEMBL31358668 0.83 MAPT (0.51) KMT2ANPSR1PKMKDM4EBRAF
SCHEMBL31358724 0.83 PIK3CG (0.56) KMT2ANPSR1PKMKDM4EMAPT
SCHEMBL31358800 0.82 KMT2A (0.60) KMT2ANPSR1PKMKDM4EBRAF
SCHEMBL31358847 0.80 GSK3A (0.58) KMT2ANPSR1PKMKDM4EBRAF
SCHEMBL31358735 0.79 KMT2A (0.57) KMT2ANPSR1PKMKDM4EBRAF
SCHEMBL31358808 0.79 KMT2A (0.57) KMT2ANPSR1PKMKDM4EBRAF

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250026741-A1 INHIBITORS OF THE ONCOGENIC SHP2 PHOSPHATASE AND USES THEREOF Sanford Burnham Prebys Medical Discovery Institute 2025-01-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250026741-A1 INHIBITORS OF THE ONCOGENIC SHP2 PHOSPHATASE AND USES THEREOF PTPN18, PTPN7, PTPN1 KMT2A 1043/4885NPSR1 4230/4885PKM 4300/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.